Abstract:Objective: To characterize the initial clinical presentation of spinocerebellar ataxias (SCA) type 1, 2, 3, and 6. Background: The SCAs are a group of genetically and clinically diverse neurodegenerative diseases and the understanding of initial clinical presentation of each SCA type will help pinpoint the clinical diagnosis. Methods: The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 317 participants with SCA 1, 2, 3 and 6 from 12 medical centers in the United States. The initial presentation to ataxia specialist was recorded, including age of onset of any gait, speech, vision, and hand abnormalities. Since the majority of patients had gait abnormality as the first symptom, we divided SCA patients into two groups: gait onset group or non-gait onset group. We compared the number of pathological CAG repeats and the age of disease onset between the gait onset group and the non-gait onset group using t-test or the Wilcoxon Mann-Whitney test. Results: The majority of SCA patients had gait problems initially and the percentage of these patients was similar across different types of SCAs (92.3[percnt] in SCA1, 87.0[percnt] in SCA2, 87.5[percnt] in SCA3, and 83.8[percnt] in SCA6, p= 0.59). The pathological CAG repeat expansions were similar between gait onset group and non-gait onset group in all four types of SCA patients. In addition, the disease onset for non-gait group in SCA2 patients was 9 years earlier than their counterpart (non-gait onset group 28.2 ± 14.8 years old vs. gait onset 37.2 ± 11.4 years old, p= 0.039). We did not observe any differences in disease onset between gait onset group and non-gait onset group in SCA1, 3, and 6. Conclusions: Gait abnormality is the most common initial presentation of SCAs. Interestingly, SCA2 patients with non-gait onset tend to have a younger disease onset, which might represent a subtype of SCA2. Disclosure: Dr. Luo has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Figueroa has nothing to disclose. Dr. Pulst has received personal compensation for activities with Ataxion Therapeutics and Roche Pharmaceuticals as a consultant. Dr. Pulst has received personal compensation in an editorial capacity for AAN Neurology: Genetics. Dr. Pulst has received (roy Dr. Perlman has received research support from Santhera Pharmaceuticals. Dr. Wilmot has nothing to disclose. Dr. Gomez has nothing to disclose. Dr. Schmahmann has received license fees payments from Massachusetts General Hospital. Dr. Paulson has received personal compensation for activities with Shire Human Genetic Therapy. Dr. Shakkottai has nothing to disclose. Dr. Ying has nothing to disclose. Dr Zesiewicz has received research support from FARA. Dr. Bushara has nothing to disclose. Dr. Geschwind has received personal compensation for activities with Best Doctors, Advanced Medical, Guidepoint Global, Gerson-Lehrman Group, and Quest Diagnostics. Dr. Geschwind has received research support from NIH/NIA, the Tau Consortium, Michael J. H Dr. Xia has nothing to disclose. Dr. Subramony has received research support from ISIS Pharmaceuticals, REATA Pharmaceuticals and Horizon Pharmaceuticals. Dr. Ashizawa has received royalty payments from Baylor College of Medicine. Dr. Kuo has nothing to disclose.

Spinocerebellar Ataxia Type 6: Systematic Patho-Anatomical Study Reveals Different Phylogenetically Defined Regions of the Cerebellum and Neural Pathways Undergo Different Evolutions of the Degenerative Process

A neuropathological study at autopsy of early onset spinocerebellar ataxia 6.

Spinocerebellar Ataxia Type 6 in Mainland China: Molecular and Clinical Features in Four Families.

Research on gene mutation and clinical characteristics of hereditary spinocerebellar ataxia type 6 from 2 Chinese families

[Frequency Analysis of Autosomal Dominant Spinocerebellar Ataxias in Han Population in the Chinese Mainland and Clinical and Molecular Characterization of Spinocerebellar Ataxia Type 6].

Clinical,pathological and molecular biological study on a Chinese family of Spinocerebellar Ataxia type 6

The Clinical Features and Gene Mutation Analysis in a Pedigree of Spinocerebellar Ataxia Type 7

Cerebellar heterogeneity and selective vulnerability in spinocerebellar Ataxia type 1 (SCA1)

Mitochondrial damage and impaired mitophagy contribute to disease progression in SCA6

Clinical and Genetic Study of a Chinese Family with Spinocerebellar Ataxia Type 7.

Cerebral cortical functional hyperconnectivity in a mouse model of spinocerebellar ataxia type 8 (SCA8)

Recent Progress in the Molecular Genetics of Spinocerebellar Ataxias (Scas)

Single-nuclei RNA sequencing uncovers non-cell autonomous changes in cerebellar astrocytes and oligodendrocytes that may contribute to Spinocerebellar Ataxia Type 1 (SCA1) pathogenesis

Beneficial Effects of Cerebellar Rtms Stimulation on a Patient with Spinocerebellar Ataxia Type 6

Single nuclei RNA sequencing investigation of the Purkinje cell and glial changes in the cerebellum of transgenic Spinocerebellar ataxia type 1 mice

The Pattern and Staging of Brain Atrophy in Spinocerebellar Ataxia Type 2 (SCA2): MRI Volumetrics from ENIGMA-Ataxia

The Initial Clinical Presentation of Spinocerebellar Ataxias Type 1, 2, 3, and 6 (P6.393)

Compressed Cerebellar Functional Connectome Hierarchy in Spinocerebellar Ataxia Type 3.

Clinical Characteristics, Radiological Features and Gene Mutation in 10 Chinese Families with Spinocerebellar Ataxias

Identifying extracerebellar characteristics in a large cohort of 319 Chinese patients with spinocerebellar ataxia type 3

Infantile onset spinocerebellar ataxia with sensory neuropathy (IOSCA): neuropathological features